Aug 21 2010
IRIDEX Corporation, manufacturer of laser-based medical devices, has received a US patent for its MicroPulse technology. The patent is named as ‘Laser System with Short Pulse Characteristics And Its Method Of Use’. IRIDEX’s MicroPulse technology offers dose control laser energy during eye procedure.
The MicroPulse technology assists ophthalmologists to treat patients with diabetic retinopathy and similar glaucoma and retinal disorders. Unlike the conventional continuous wave laser treatment, the MicroPulse technology-based treatments deliver better results and cause minimal damage to the retinal structures.
The new patent explains that visible wavelength lasers can produce laser energy in a packet of discrete pulses, whereas the visible laser photocoagulators utilizing traditional technology delivers laser energy in a single optical dose. Users can easily alter the MicroPulse parameters such as amplitude, interpulse interval and duration or can select factory or customized presets to alter the parameters accordingly.
The MicroPulse mode can be easily deactivated and activated, enabling both MicroPulse and traditional laser delivery from a single delivery device.